Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 3,528Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 12SANOFI AVENTIS US

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2034-02-04

TERIFLUNOMIDE

US Patent Number : 9186346

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code : U-1786

Delist Requested :

Patent Use Description : TREATMENT OF PATIENTS ...

Patent Expiration Date : 2034-02-04

Sanofi Company Banner

02

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2026-09-12

TERIFLUNOMIDE

US Patent Number : 6794410

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code : U-1285

Delist Requested :

Patent Use Description : TREATMENT OF PATIENTS ...

Patent Expiration Date : 2026-09-12

Sanofi Company Banner

03

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2026-09-12

TERIFLUNOMIDE

US Patent Number : 6794410

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code : U-1285

Delist Requested :

Patent Use Description : TREATMENT OF PATIENTS ...

Patent Expiration Date : 2026-09-12

Sanofi Company Banner

04

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2034-02-04

TERIFLUNOMIDE

US Patent Number : 9186346

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code : U-1786

Delist Requested :

Patent Use Description : TREATMENT OF PATIENTS ...

Patent Expiration Date : 2034-02-04

Sanofi Company Banner

05

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2030-09-14

TERIFLUNOMIDE

US Patent Number : 8802735

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-09-14

Sanofi Company Banner

06

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2030-09-14

TERIFLUNOMIDE

US Patent Number : 8802735

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-09-14

Sanofi Company Banner

07

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2031-03-14

TERIFLUNOMIDE

US Patent Number : 8802735*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-03-14

Sanofi Company Banner

08

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2031-03-14

TERIFLUNOMIDE

US Patent Number : 8802735*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-03-14

Sanofi Company Banner

09

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2027-03-12

TERIFLUNOMIDE

US Patent Number : 6794410*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-03-12

Sanofi Company Banner

10

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2027-03-12

TERIFLUNOMIDE

US Patent Number : 6794410*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 202992

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-03-12

Sanofi Company Banner